News & Updates

Nintedanib may spare lung in COVID-19

09 Jun 2021 by

The antifibrotic agent nintedanib appears to help minimize lung injury in patients with severe COVID-19 undergoing mechanical ventilation, with a recent study showing that treatment lowers the likelihood of acute respiratory failure, shortens ventilation time, and reduces the volume of high-attenuation areas on imaging.

Nintedanib may spare lung in COVID-19

09 Jun 2021

Tocilizumab administration for severe COVID-19: Timing matters

09 Jun 2021 by

Early administration (ie, pre-intubation/noninvasive ventilation) of the interleukin-6 receptor blocker tocilizumab in patients with severe COVID-19 led to more favourable outcomes compared with late administration (ie, post-intubation/noninvasive ventilation), according to data presented at ATS 2021.

Tocilizumab administration for severe COVID-19: Timing matters

09 Jun 2021

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

06 Jun 2021 by

The specific TSLP* inhibitor tezepelumab significantly reduces exacerbation rates across a broad spectrum of patients with severe, uncontrolled asthma, regardless of the status of key inflammatory biomarkers, according to the NAVIGATOR study presented at ATS 2021.

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

06 Jun 2021

Breakthrough infections after COVID-19 vaccines: Who is at risk?

05 Jun 2021 by

While the rate of breakthrough infections is low among people who have been fully vaccinated against COVID-19, researchers found that older age and having anaemia were associated with an increased risk of such infections.

Breakthrough infections after COVID-19 vaccines: Who is at risk?

05 Jun 2021

Asthma does not compromise mental health in teens

04 Jun 2021

Asthma does not seem to hurt mental wellbeing among adolescents, though it may worsen general health, a recent study has found.

Asthma does not compromise mental health in teens

04 Jun 2021

Long-term study findings reflect potential of sotatercept for PAH

04 Jun 2021 by

The efficacy and safety of the novel, first-in-class, selective fusion protein sotatercept were sustained or enhanced for up to 48 weeks when added to standard of care (SOC) for the treatment of pulmonary arterial hypertension (PAH), according to interim findings of the ongoing open-label extension (OLE) period of the phase II PULSAR trial presented at ATS 2021.

Long-term study findings reflect potential of sotatercept for PAH

04 Jun 2021

Current smokers more likely to experience COVID-19 symptoms

03 Jun 2021 by

Individuals who are smokers are more likely to report the classic symptoms suggestive of COVID-19 (fever, new persistent cough, and breathlessness) and have a greater symptom burden than non-smokers, a prospective UK-based study found.

Current smokers more likely to experience COVID-19 symptoms

03 Jun 2021

4-month rifapentine regimen on par with 6-month standard TB care

02 Jun 2021 by

A shorter treatment course of 4 months with a rifapentine-based regimen containing moxifloxacin proves to be noninferior to a standard 6-month regimen in patients with drug-susceptible tuberculosis, a phase III randomized trial has shown.

4-month rifapentine regimen on par with 6-month standard TB care

02 Jun 2021

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)

02 Jun 2021

New drug applications approved by US FDA as of 16-31 May 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)

02 Jun 2021

Short-course amoxicillin: Good enough for paediatric CAP?

01 Jun 2021 by

A short-course high-dose amoxicillin regimen may be sufficient in treating children with community-acquired pneumonia (CAP) who do not require hospitalization, according to results of the SAFER* trial.

Short-course amoxicillin: Good enough for paediatric CAP?

01 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Nintedanib may spare lung in COVID-19

Nintedanib may spare lung in COVID-19

Tocilizumab administration for severe COVID-19: Timing matters

Tocilizumab administration for severe COVID-19: Timing matters

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

Breakthrough infections after COVID-19 vaccines: Who is at risk?

Breakthrough infections after COVID-19 vaccines: Who is at risk?

Asthma does not compromise mental health in teens

Asthma does not compromise mental health in teens

Long-term study findings reflect potential of sotatercept for PAH

Long-term study findings reflect potential of sotatercept for PAH

Current smokers more likely to experience COVID-19 symptoms

Current smokers more likely to experience COVID-19 symptoms

4-month rifapentine regimen on par with 6-month standard TB care

4-month rifapentine regimen on par with 6-month standard TB care

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)

Short-course amoxicillin: Good enough for paediatric CAP?

Short-course amoxicillin: Good enough for paediatric CAP?